<DOC>
	<DOCNO>NCT01420926</DOCNO>
	<brief_summary>This randomized phase II trial study well give decitabine without bortezomib work treat old patient acute myeloid leukemia . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . It yet know whether decitabine work well give without bortezomib treat acute myeloid leukemia .</brief_summary>
	<brief_title>Decitabine With Without Bortezomib Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine treatment old acute myeloid leukemia ( AML ) patient decitabine bortezomib significantly improve overall survival time older AML patient compare decitabine alone . SECONDARY OBJECTIVES : I . To determine rate complete remission ( CR CR + incomplete blood count recovery [ CRi ] ) 2 treatment regimen proposal . II . To determine overall survival , progression-free survival , disease-free survival treatment regimens study . III . To determine whether ongoing treatment regimen prolong overall survival even absence complete remission . IV . To describe frequency severity adverse event , well tolerability regimens patient treat study . V. To describe interaction pretreatment disease patient characteristic include morphology , cytogenetics , molecular genetics , white blood cell ( WBC ) count , blood bone marrow blast count , age , performance status comprehensive geriatric assessment clinical outcome . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : REMISSION INDUCTION THERAPY : Patients receive decitabine intravenously ( IV ) 1 hour daily ( QD ) day 1-10 . Treatment repeat every 28 day 2-4 course absence disease progression unacceptable toxicity . Patients achieve CR CR CRi proceed continuation therapy . Patients achieve CR CR CRi proceed maintenance therapy . CONTINUATION THERAPY : Patients receive decitabine IV 1 hour QD day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Patients receive decitabine IV 1 hour QD day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM II : REMISSION INDUCTION THERAPY : Patients receive decitabine IV 1 hour QD day 2-11 bortezomib subcutaneously ( SC ) day 1 , 4 , 8 , 11 . Treatment repeat every 28 day 2-4 course absence disease progression unacceptable toxicity . Patients achieve CR CRi proceed continuation therapy . Patients achieve CR CR CRi proceed maintenance therapy . CONTINUATION THERAPY : Patients receive bortezomib SC day 1 decitabine IV 1 hour QD day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Patients receive bortezomib SC day 1 decitabine IV 1 hour QD day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month 2 year , every 3 month 2 year , year 6 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Unequivocal pathologic diagnosis AML ( &gt; = 20 % blast bone marrow base World Health Organization [ WHO ] criterion ) EXCLUDING : Acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) ; promyelocytic leukemia ( PML ) retinoic acid receptor , alpha ( RARA ) Acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 ) ; runtrelated transcription factor 1 ( RUNX1 ) runtrelated transcription factor 1 ; translocate , 1 ( RUNXT1 ) determine Ohio State University ( OSU ) Molecular Reference Laboratory , per Cancer Leukemia Group B ( CALGB ) 20202 ; however patient ( 1 ) &gt; = 75 year ; and/or ( 2 ) ejection fraction &lt; 40 % ; and/or ( 3 ) performance status &gt; 2 , may register CALGB 20202 register treat CALGB 11002 prior receive fmsrelated tyrosine kinase 3 ( FLT3 ) mutation corebinding factor ( CBF ) molecular screen result CALGB 20202 Acute myeloid leukemia inv ( 16 ) ( p13.1 ; q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; corebinding factor , beta subunit ( CBFB ) myosin , heavy chain 11 , smooth muscle ( MYH11 ) determine OSU Molecular Reference Laboratory , per CALGB 20202 ; however patient ( 1 ) &gt; = 75 year ; and/or ( 2 ) ejection fraction &lt; 40 % ; and/or ( 3 ) performance status &gt; 2 , may register CALGB 20202 register treat CALGB 11002 prior receive FLT3 mutation CBF molecular screening result CALGB 20202 Absence FLT3 mutation ( internal tandem duplication [ ITD ] point mutation ) determine OSU Molecular Reference Laboratory , per CALGB 20202 ; however patient ( 1 ) &gt; = 75 year ; and/or ( 2 ) ejection fraction &lt; 40 % ; and/or ( 3 ) performance status &gt; 2 , may register CALGB 20202 register treat CALGB 11002 prior receive FLT3 mutation CBF molecular screening result CALGB 20202 No prior treatment AML except : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea Cranial radiotherapy ( RT ) central nervous system ( CNS ) leukostasis ( one dose ) Growth factor/cytokine support AML patient antecedent hematologic disorder ( AHD ) myelodysplastic syndrome ( MDS ) eligible trial provide received treatment AHD MDS cytotoxic chemotherapy ( e.g. , cytarabine , daunorubicin , etc . ) , decitabine , bortezomib ; patient may previously treat azacitidine last dose &gt; = 90 day prior start 11002 AML patient therapyrelated myeloid neoplasm ( tMN ) eligible receive radiation therapy chemotherapy ( include hormonal therapy ) primary malignancy disorder &gt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>